Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date29 Jul 2011 |
Target- |
MechanismImmunomodulators |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Jun 1930 |
A Phase 1 Study to Evaluate the Immunologic Mechanisms Underlying Wart Resolution After Intralesional Immunotherapy With Candida Antigen
The purpose of this study is to look at how people respond to the treatment of warts through use of the Candida antigen to get an immune response to rid the body of human papillomavirus (HPV). The immune system is the part of the body that fights infections like HPV which causes warts. This research study will examine the response of your wart when injected with a portion of a common yeast (candida) which is the study drug. Your immune system response will also be looked at by doing a test called an ELISPOT assay. This test is done on blood samples. The results of this test may help us to determine how the Candida antigen affects your wart.
100 Clinical Results associated with Allermed Laboratories, Inc.
0 Patents (Medical) associated with Allermed Laboratories, Inc.
100 Deals associated with Allermed Laboratories, Inc.
100 Translational Medicine associated with Allermed Laboratories, Inc.